The aim of the work: to identify clinical and pathogenetic features and improve the diagnosis of coronary heart disease combined with type 2 diabetes mellitus in patients who have su—ered from coronavirus infection. Material and methods. 120 patients with stable coronary artery disease combined with DM were examined. The patients were divided into two groups: the main group (history of COVID) and the comparison group (without COVID). Laboratory tests determined highly sensitive C-reactive protein (HCRP), D-dimer, vascular endothelial growth factor (VEGF-A), plasma lipid spectrum and indicators of antioxidant protection of the body, and instrumental electrocardiography, a test with metered physical activity on a treadmill, daily Holter electrocardiography monitoring, ultrasound examination of the brachial artery to determine endothelium dependent vasodilation. The clinical picture of coronary heart disease combined with type 2 diabetes in patients who have been infected with SARS-CoV-2 is characterized by a higher level of o–ce blood pressure, increased cardiac, psychosomatic and metabolic disorders. The results of the study indicate that coronary heart disease combined with type 2 diabetes in patients who have been infected with SARS-CoV-2 in 56.2% of cases occurs in the form of painless myocardial ischemia, manifested by an increase in the maximum degree of ST segment depression and the duration of its episodes, as well as an increase in daily myocardial ischemia with a decrease in the threshold heart rate during attacks. Laboratory parameters in these patients are characterized by dyslipidemia, an increase in the content of VEGF-A, an increased level of D-dimer and (an indicator of in˜ammation) HCRP, and a signi†cant decrease in the antioxidant activity of blood plasma. Conclusions. Coronary heart disease in patients with type 2 diabetes who had COVID, in 56.2% of cases, occurred in the form of painless myocardial ischemia and was accompanied by the occurrence of cardiac, psychosomatic (astheno-neurotic and asthenovegetative syndromes) and metabolic disorders. In the post-covid period, these patients had impaired lipid metabolism, an increase in VEGF-A with pronounced endothelial dysfunction, an increase in D-dimer and HCRP with a decrease in the total antioxidant activity of blood plasma.
coronary heart disease, coronavirus infection, comorbid pathology, endothelial dysfunction, painless myocardial ischemia
1. Zhou Y., Zhu X., Cui H., et al. The Role of the VEGF Family in Coronary Heart Disease. Frontiers in Cardiovascular Medicine. 2021;8:1-16. doihttps://doi.org/10.3389/fcvm.2021.738325.
2. Chen D., Li X., Song Q., et al. Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open. 2020;3(6):e2011122.
3. O’Neill L. A., Kishton R. J., Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553-565. doi:10.1038/ nri.2016.70.
4. Batishcheva G. A., Goncharova N. Yu., Ketova E. S. The effect of coronavirus infection on the state of carbohydrate and lipid metabolism. Scientific and medical bulletin of the Central Chernozem region. 2022;89:4-8 (in Russ.).
5. Obedkova N. Yu., Mal G. S., Melikhova E. M., et al. Progression of hyperlipidemia as a result of new coronavirus infection in patients with coronary heart disease. Innova. 2023;9(2):59-62 (in Russ.).
6. Yezhov M. V., Batluk T. I., Tokmin D. S. et al. The prevalence of dyslipidemia before and against the background of the COVID-19 pandemic. Analysis of a large laboratory database. Atherosclerosis and dyslipidemia. 2023; 2
7. Khaisheva L. A., Khorolets E. V., Kuroedov V. A. et al. Study of angiogenesis factors in patients with acute myocardial infarction. South Russian Journal of Therapeutic Practice. 2020;1(2):38-45 (in Russ.).
8. Holm P. W., Slart R. H., Zeebregts C. J. et al. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med. 2009;41(4):257-264. doihttps://doi.org/10.1080/07853890802516507.
9. Flores-Mateo G., Carrillo-Santisteve P., Elosua R. et al. Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies. Am J Epidemiol. 2009;170(2):135-147. doihttps://doi.org/10.1093/aje/kwp112.
10. Gawron-Skarbek A., Chrzczanowicz J., Kostka J., et al. Physical Activity, Aerobic Capacity, and Total Antioxidant Capacity in Healthy Men and in Men with Coronary Heart Disease. Oxidative Medicine Celluiar Longevity.
11. Bekbossynova M., Tauekelova A., Sailybayeva A. et al. Unraveling Acute and Post COVID Cytokine Patterns to Anticipate Future Challenges. J Clin Med. 2023;12(16):5224. doihttps://doi.org/10.3390/jcm12165224.
